Together, the high expression of GADD45B in a subset of these cancers, including diffuse large B cell lymphoma (DLBCL) and other types of lymphoma (Lam et al., 2005, Ngo et al., 2006, Tracey et al., 2005), and the selective toxicity of DTP3 in DLBCL, Burkitt’s lymphoma and promonocytic leukemia cell lines, imply that GADD45β/MKK7 antagonists may have broader therapeutic potential beyond MM, in other areas of unmet need within oncology. Here, GADD45B is linked to leukemia.